

IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

| STATE OF OKLAHOMA, ex rel., | |
|--|------------------------------|
| MIKE HUNTER, | |
| ATTORNEY GENERAL OF OKLAHOMA,) | |
|) Plaintiff,) | |
| , , , , , , , , , , , , , , , , , , , | Case No. CJ-2017-816 |
| vs. | Judge Thad Balkman |
|) | - |
| (1) PURDUE PHARMA L.P.; | |
| (2) PURDUE PHARMA, INC.; | |
| (3) THE PURDUE FREDERICK COMPANY;) | |
| (4) TEVA PHARMACEUTICALS USA, INC.;) | STATE OF OKLAHOMA S.S. |
| (5) CEPHALON, INC.; | CLEVELAND COUNTY J |
| (6) JOHNSON & JOHNSON; | FILED |
| (7) JANSSEN PHARMACEUTICALS, INC; | |
| (8) ORTHO-MCNEIL-JANSSEN | AUG 22 2018 |
| PHARMACEUTICALS, INC., n/k/a | |
| JANSSEN PHARMACEUTICALS;) | In the office of the |
| (9) JANSSEN PHARMACEUTICA, INC., | Court Clerk MARILYN WILLIAMS |
| n/k/a JANSSEN PHARMACEUTICALS, INC.;) | Godit Giovi |
| (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,) f/k/a ACTAVIS, INC., f/k/a WATSON) | |
| PHARMACEUTICALS, INC.; | |
| (11) WATSON LABORATORIES, INC.; | |
| (12) ACTAVIS LLC; and | |
| (13) ACTAVIS PHARMA, INC., | |
| f/k/a WATSON PHARMA, INC., | |
|) | |
| Defendants. | |
| , | |

THE STATE'S EMERGENCY MOTION TO SHOW CAUSE FOR JANSSEN'S INTENTIONAL DISREGARD OF COURT ORDER AND FAILURE TO PROVIDE WITNESS AS ORDERED BY THE COURT

Like Purdue, Janssen has just demonstrated its complete disrespect and disregard for the Orders of this Court. On August 21, Janssen boldly proclaimed in writing that it will not comply with Judge Balkman's August 10, 2018 Order from the Bench requiring Janssen to provide a witness for the deposition noticed before August 30. *See* Exhibit A. Instead, Janssen claims this witness is not available *until October*. For the State to comply with this Court's Scheduling Order

and proceed to trial May 28, 2019, the Court must order Janssen to comply with the Court's Orders and the Oklahoma Discovery Code and must sanction Janssen for non-compliance. Janssen apparently has no intention of doing so on its own. The State cannot wait until October to start taking depositions *it noticed in May*, as Janssen now suggests the State must do. It will not work.

Janssen's Counsel's letter regarding the hearing on August 10 is aggressively cute in the manner in which it cherry picks certain statements from the hearing. *See id.* The letter, however, makes no mention of the Court's Order from the Bench that all depositions previously noticed, argued and ruled upon by Judge Hetherington must take place as noticed on or before August 30, 2018. *See* Exhibit C at 55:12-20; 57:21-23. Nor does Janssen's letter cite any statement or objection made by Janssen or its Counsel at the August 10 hearing regarding this Order. Janssen was at the hearing and was silent on this issue. Further, to the extent that did not already constitute waiver and the Court's Order was not enough, Janssen did not file a motion to quash this deposition by the deadline under the standing order of this Court for discovery motions. The deadline to file such a motion was last Friday in anticipation of the August 31 hearing regarding any depositions noticed *after* August 30. Janssen filed no motions to quash related to those depositions and has therefore further waived any arguments regarding their scope.

The history of this notice is set forth below and is very similar to the timeline at issue in the State's Emergency Motion as to Purdue:

- The State first noticed this deposition on April 2, 2018, for the deposition to occur on April 10th— Janssen refused to appear (*See* Plaintiff's Second Motion to Compel Discovery, April 5, 2018).
- Janssen moved to quash. Judge Hetherington ruled that the deposition could go forward in a narrow capacity than the State originally noticed it, so, on May 4, 2018, the State renoticed the deposition as ordered by Judge Hetherington for the deposition to occur on May 30th.
- On May 14, Janssen provided that the noticed date "will not work," but that a witness

should be available the week of June 11 or June 18. As a compromise, the State suggested the deposition occur on June 8th. Janssen would not agree.

- On May 25, the State re-noticed the deposition for a third time as Janssen still had not provided an agreed date. The State noticed the deposition to occur June 11—during the time-frame Janssen indicated a witness could be available.
- Once again, however, Janssen would not agree to put up a witness on the noticed date, instead responding that a witness would available for deposition in Oklahoma City on June 21, 2018.
- On May 31, the State re-noticed the deposition for a fourth time, scheduling the deposition for the exact date and location requested by Janssen.
- Janssen then consented to the fraudulent removal of the case before the deposition could go forward.
- On August 6, 2018, immediately after Remand, the State re-noticed the deposition for a fifth time take place on August 28th (See Exhibit D).
- Janssen never responded in any way and it did not file a Motion to Quash.
- During the hearing on August 10, 2018, the Court ordered: "Those depositions that were noticed before the removal that went through the process where you all presented arguments and that Judge Hetherington ruled on, I'm going to decide that those are not void, that they should proceed; that all those before August 30th should go ahead. I'm going to instruct the parties to move forward with those." (emphasis added) (Exhibit C at 55:12-20).
- The Court further confirmed: "Those that were previously noticed and argued and ruled upon by Judge Hetherington and that will take place between now and August 30th, go ahead and do those." (Id. at 57:21-23) (emphasis added).
- Janssen did not object, comment or complain in any way about the Court's Order. To the contrary, Janssen said nothing. Silence is a waiver and, thus, Janssen waived any challenge to the Court's Order.
- Under the Court's standing discovery orders, even if Janssen could still move to quash either deposition again, it had to file such a motion by Friday, August 17, 2018. It did not file a motion. Thus, while any repeated motion to quash would have been dubious, Janssen's failure to file it constitutes a waiver of any challenge to the date, time or location of the deposition.

Janssen, like Purdue, is delaying this deposition to attempt to avoid this trial. Janssen tried to force the State to actually go to the MDL by consenting to a fraudulent removal. That did not

work. And now, facing a trial, Janssen is trying to buy time. Janssen claims it will not make this witness available until *October 10. See* Exhibit A. Coincidentally, Janssen is driving this deposition closer and closer to the recently revised deposition schedule set forth by the MDL court in its most recent case management order. *See* Exhibit B. Undoubtedly, the next thing the State will see from Janssen will be another cute letter suggesting that the State *must* coordinate with the parties in the MDL regarding the scheduling and taking of this deposition. No matter how many times Janssen, or any Defendant, loses its various bids to force this case and this Court into the jurisdiction of the MDL, Janssen continues to try to do so. Why? The State has said it at every hearing: delay. Janssen is trying to control this Court and this docket. If the Court does not enforce the rules, its Scheduling Order, and the scheduling of depositions thereunder, then the rules and the Scheduling Order are meaningless. Which is exactly what Janssen wants. As explained in the State's similar motion against Purdue, such open and blatant disregard for this Court and the judicial process simply cannot be tolerated.¹

Even ignoring everything that happened with respect to this deposition notice prior to removal, as soon as this case was remanded, the State served the notice for this deposition on August 6 for the deposition to occur on August 28. Exhibit D. At no point since then has Janssen contested this deposition notice. At no point has Janssen filed a motion to quash or for a protective order as required under the Oklahoma Discovery Code. At no point did Janssen object to or contest the Court's specific ruling regarding this deposition at the August 10 hearing that it proceed as noticed. Janssen has no basis under the rules for not appearing on August 28 and providing sworn testimony for the topic noticed on that date. As the Court ordered, the parties can address the remaining topics that were noticed to occur after August 30 at the hearing on August 31. But, the

¹ The State hereby incorporates by reference its Emergency Motion to Show Cause for Purdue's Intentional Disregard of Two Court Orders and Failure to Provide Witness as Ordered by the Court, dated August 20, 2018.

State must be permitted to immediately proceed with the deposition as noticed for August 28.

For all the same reasons as set forth in Plaintiff's Emergency Motion to Show Cause for Purdue's Intentional Disregard of Two Court Orders and Failure to Provide Witness as Ordered by the Court, the Court should grant this Motion as to Janssen and Order that Janssen:

- (1) Appear at the location designated in the notice on August 28 for the deposition noticed by the State on that date:
- (2) Show cause as to why it should not be held in contempt for violating the Court's Order regarding this deposition; and
- (3) Failing to show cause, should have its defenses stricken for repeated discovery abuse.

Respectfully submitted,

Michael Burrage QBA No. 1350 Reggie Whitten BA No. 9576

WHITTEN BURRAGE

512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

mburrage@whittenburragelaw.com

rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503

ATTORNEY GENERAL FOR

THE STATE OF OKLAHOMA

Abby Dillsaver, OBA No. 20675

GENERAL COUNSEL TO

THE ATTORNEY GENERAL

Ethan A. Shaner, OBA No. 30916

DEPUTY GENERAL COUNSEL

313 N.E. 21st Street

Oklahoma City, OK 73105

Telephone:

(405) 521-3921

Facsimile:

(405) 521-6246

Emails:

abby.dillsaver@oag.ok.gov

ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 Trey Duck, OBA No. 33347 Drew Pate, *pro hac vice* Lisa Baldwin, OBA No. 32947 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 Telephone: (405) 601-1616

Email:

gcoffee@glenncoffee.com

ATTORNEYS FOR PLAINTIFF

CERTIFICATE OF SERVICE

I certify that a true and correct copy of the above and foregoing was emailed on August 21, 2018 to:

Sanford C. Coats
Cullen D. Sweeney
Joshua D. Burns
CROWE & DUNLEVY, P.C.
Braniff Building
324 N. Robinson Ave., Ste. 100
Oklahoma City, OK 73102

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131

Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072 Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul A. LaFata **Dechert LLP** Three Bryant Park New York, New York 10036

Robert G. McCampbell Travis J. Jett Nicholas Merkley GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Charles C. Lifland Jennifer D. Cardelus David K. Roberts O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Jonathan S. Tam QUINN EMANUEL URGUHART & SULLIVAN, LLP 50 California Street San Francisco, CA 94111

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

Michael Burrage

EXHIBIT A



O'Melveny & Myers LLP 1625 Eye Street, NW Washington, DC 20006-4061 T: +1 202 383 5300 F: +1 202 383 5414 omm.com File Number: 427.892-297

August 21, 2018

Steve Brody D: +1 202 383 5167 sbrody@omm.com

VIA E-MAIL

Reggie Whitten
Michael Burrage
WHITTEN BURRAGE
512 N. Broadway Avenue, Suite 300
Oklahoma City, OK 73102

Re: State of Oklahoma v. Purdue Pharma L.P. et al., No. CJ-2017-816

Dear Reggie and Mike:

On August 6, the State noticed a 12 O.S. § 3230(C)(5) deposition for August 28, 2018 regarding Janssen's efforts to "address, fight, or abate the opioid crisis." As you know, the State did not contact us first to determine whether August 28 would work for Janssen's counsel and witness. It does not. Two days later, on August 8, the State served an additional 41 corporate representative notices on Janssen. These notices would require Janssen's counsel and witnesses to appear in Oklahoma on 41 separate days between September 21, 2018 and December 5, 2018.

We were, however, pleased to hear Mr. Beckworth's acknowledgment at the Court's August 10 status conference that although "this list of deposition notices ... goes on forever," "the length and number is due to the fact that" the State "listed the topics discreetly." Tr., 8/10/18 at 34:19-21. Mr. Beckworth went on to indicate, "I do not think and I would hope that one witness can testify on multiple topics, and that'll cut down the number." *Id.* at 34:21-23. This will be true of the Janssen's witness on the following topics:

- All actions and efforts previously taken, currently under way, and actions planned and expected to take place in the future which seek to address, fight or abate the opioid crisis.
- Research conducted, funded, directed and/or influenced by You, in whole or in part, related to opioid risks and/or efficacy.
- Your scientific support for Your marketing statements and representations regarding the risks and benefits of opioids.
- Your research conducted, funded, directed and/or influenced, in whole or in part, related to pseudoaddiction.

- Your scientific support for Your marketing statements and representations regarding pseudoaddiction.
- Your use and/or establishment of any opioid abuse and diversion program You
 established and implemented to identify Healthcare Professionals' and/or pharmacies'
 potential abuse or diversion of opioids.
- · Amounts spent by You on research and development for opioids.
- Your use of clinical trial companies regarding opioids and/or pain management.
- Clinical trials funded, sponsored, and/or conducted by You regarding opioids and/or pain management.
- All opioids manufactured, owned, contemplated, developed, and/or in-development by You including the nature of each such opioid, its intended use, and the stage of development of each (e.g. released to market, in development, abandoned).
- All drugs for opioid use disorder manufactured, owned, contemplated, developed, and/or
 in-development by You including the nature of each such opioid use disorder drug, its
 intended use, the stage of development of each (e.g. released to market, in
 development, abandoned), and profits earned by You from the sale of any such drug in
 Oklahoma.
- All drugs for the treatment of opioid overdose manufactured, owned, contemplated, developed, and/or in-development by You including the nature of each such opioid overdose drug, its intended use, the stage of development of each (e.g. released to market, in development, abandoned), and profits earned by You from the sale of any such drug in Oklahoma.
- Policies, practices, and procedures regarding complaints You received related to addiction or abuse of Your opioids in Oklahoma.

Our witness is available on October 10 and, if necessary, October 11, 2018, in Oklahoma City. We trust this will provide the State with enough time to prepare for the deposition despite the fact that certain of the topics were originally noticed for later dates (including four that were noticed for November). Please confirm whether these dates will work for the State's counsel.

Thank you for your attention to the foregoing.

Sincerely,

Steve Brody

for O'MELVENY & MYERS LLP

cc: Counsel of Record

EXHIBIT B

Case: 1:17-md-02804-DAP Doc #: 876 Filed: 08/13/18 1 of 2. PageID #: 20533

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION

| OPIATE LITIGATION) JUDGE POLSTER | |
|------------------------------------|--------------|
|) JUDGE POLSTER | |
| | |
|) | |
|) <u>CASE MANAGEMENT ORDER</u> | <u>NO. 7</u> |
|) <u>SETTING NEW DEADLINES FO</u> | R |
|) TRACK ONE CASES | |

This Court earlier set case management deadlines in connection with the "Track One Cases." See CMO-1 at 6-8 (docket no. 232). The parties unanimously requested extension of those deadlines and submitted various proposed schedules. Having reviewed those proposals, the Court now enters the following amended case management schedule.

August 31, 2018 – The parties shall exchange lists of initial fact witness depositions. If the parties agree, depositions may proceed immediately. As much as possible, however, depositions shall be taken of witnesses only after relevant documents have been produced. Thus, the majority of depositions shall occur between October 25, 2018 and January 25, 2019.

October 25, 2018 – For all parties *except* retail pharmacy defendants: (1) production of documents shall be substantially complete; and (2) traditional 30(b)(6) depositions shall be substantially complete (i.e., 30(b)(6) depositions concerning discovery-related issues, such as types and location of documents and databases).

November 9, 2018 – For retail pharmacy defendants: (1) production of documents shall be substantially complete; and (2) traditional 30(b)(6) depositions shall be substantially complete (i.e.,

Case: 1:17-md-02804-DAP Doc #: 876 Filed: 08/13/18 2 of 2. PageID #: 20534

30(b)(6) depositions concerning discovery-related issues, such as types and location of documents

and databases).

January 25, 2019 – all 30(b)(6) and fact depositions shall be completed.

February 8, 2019 – Plaintiffs shall serve expert reports and, for each expert, provide two proposed

deposition dates between February 18 and March 15, 2019.

March 26, 2019 - Defendants shall serve expert reports and, for each expert, provide two proposed

deposition dates between April 8 and May 3, 2019.

May 13, 2019, 4:00 p.m. – Deadline for *Daubert* and dispositive motions.

June 10, 2019, 4:00 p.m. – Deadline for responses to *Daubert* and dispositive motions.

July 1, 2019, 4:00 p.m. – Deadline for replies in support of *Daubert* and dispositive motions.

July 16, 2019 – Hearings on Daubert and dispositive motions, or as otherwise set by the Court, if

necessary.

August 22, 2019, 12:00 noon – Final Pretrial Hearing.

September 3, 2019 – Trial.

In a separate order, the Court will set deadlines for motions in limine, deposition

designations, jury instructions, jury questionnaire, and other pretrial submissions.

IT IS SO ORDERED.

/s/ Dan Aaron Polster

DAN AARON POLSTER

UNITED STATES DISTRICT JUDGE

Dated: August 13, 2018

2

EXHIBIT C

| 1 | IN THE DISTRICT COURT OF CLEVELAND COUNTY |
|----|---|
| 2 | STATE OF OKLAHOMA |
| 3 | STATE OF OKLAHOMA, ex rel.,) |
| 4 | MIKE HUNTER) ATTORNEY GENERAL OF OKLAHOMA,) |
| 5 | Plaintiff,) |
| 6 | vs.) Case No. CJ-2017-816 |
| 7 | (1) PURDUE PHARMA L.P.;) |
| 8 | (2) PURDUE PHARMA, INC.;) (3) THE PURDUE FREDERICK) COMPANY; |
| 9 | (4) TEVA PHARMACEUTICALS) |
| 10 | USA, INC; (5) CEPHALON, INC.;) |
| 11 | (6) JOHNSON & JOHNSON; (7) JANSSEN PHARMACEUTICALS, |
| 12 | INC.;) (8) ORTHO-MCNEIL-JANSSEN) |
| 13 | PHARMACEUTICALS, INC., n/k/a JANSSEN PHARMACEUTICALS;) |
| 14 | (9) JANSSEN PHARMACEUTICA, INC.) n/k/a JANSSEN PHARMACEUTICALS,) |
| 15 | INC.;) (10) ALLERGAN, PLC, f/k/a) |
| 16 | ACTAVIS PLC, f/k/a ACTAVIS,) INC., f/k/a WATSON) |
| 17 | PHARMACEUTICALS, INC.; (11) WATSON LABORATORIES, INC.;) |
| 18 | (12) ACTAVIS LLC; AND) (13) ACTAVIS PHARMA, INC.,) |
| | f/k/a WATSON PHARMA, INC., |
| 19 | Defendants.) |
| 20 | |
| 21 | TRANSCRIPT OF PROCEEDINGS HAD ON AUGUST 10, 2018 |
| 22 | AT THE CLEVELAND COUNTY COURTHOUSE BEFORE THE HONORABLE THAD BALKMAN |
| 23 | DISTRICT JUDGE AND WILLIAM C. HETHERINGTON, JR. |
| 24 | RETIRED ACTIVE JUDGE AND SPECIAL DISCOVERY MASTER |
| 25 | REPORTED BY: ANGELA THAGARD, CSR, RPR |

| 1 | APPEARANCES: ON BEHALF OF THE PLAINTIFF: |
|----------|---|
| 2 | MR. MICHAEL BURRAGE |
| 4 | MR. REGGIE WHITTEN MS. BROOKE HAMILTON ATTORNEYS AT LAW |
| 5 | 512 N. BROADWAY AVE, SUITE 300 OKLAHOMA CITY, OK 73102 |
| 6 | ondinioni offi, on votoz |
| 7 | MS. ABBY DILLSAVER |
| 8 | MS. DAWN CASH ATTORNEY GENERAL'S OFFICE |
| 9 | 313 N.E. 21ST STREET OKLAHOMA CITY, OK 73105 |
| 10 | |
| 11 | MR. BRADLEY BECKWORTH MR. TREY DUCK |
| 12 | MR. ANDREW G. PATE MR. ROSS LEONOUDAKIS ATTORNEYS AT LAW |
| 13 | 3600 N. CAPITAL OF TEXAS HWY, SUITE 350 AUSTIN, TX 78746-3211 |
| 14 | MODITAL TO TO SELL |
| 15 | MS. BROOKE A. CHURCHMAN ATTORNEY AT LAW |
| 16 | 3600 MARTIN LUTHER KING BLVD OKLAHOMA CITY, OK 73111-4223 |
| 17 | |
| 18 | MR. GLENN COFFEE ATTORNEY AT LAW |
| 19 | 915 N. ROBINSON AVE OKLAHOMA CITY, OK 73102 |
| 20 21 | , |
| 22 | |
| 23 | |
| 24 | |
| 25 | |

| 1 2 | ON BEHALF OF ORTHO MCNEIL JANSSEN PHARMACEUTICALS, INC.; JANSSEN PHARMACEUTICA, INC.; JANSSEN PHARMACEUTICALS, INC.; AND JOHNSON & JOHNSON: |
|-----|---|
| 3 | MR. JOHN SPARKS |
| 4 | MR. BENJAMIN H. ODOM ATTORNEYS AT LAW |
| 5 | HIPOINT OFFICE BUILDING 2500 MCGEE DRIVE, SUITE 140 |
| 6 | NORMAN, OK 73072 |
| 7 | MR. STEPHEN D. BRODY (VIA TELEPHONE) ATTORNEY AT LAW |
| 8 | 1625 EYE STREET, NORTHWEST WASHINGTON, D.C., 20006 |
| 9 | |
| LO | ON BEHALF OF PURDUE FREDERICK COMPANY; PURDUE PHARMA, INC.; AND PURDUE PHARMA LP: |
| 11 | MR. SANFORD C. COATS |
| 12 | ATTORNEY AT LAW 324 N. ROBINSON AVE, SUITE 100 |
| 13 | OKLAHOMA CITY, OK 73102 |
| L 4 | MR. JOSHUA D. BURNS |
| L5 | ATTORNEY AT LAW 324 N. ROBINSON AVE, SUITE 100 |
| 16 | OKLAHOMA CITY, OK 73102 |
| L7 | MR. JONATHAN S. TAM |
| L8 | ATTORNEY AT LAW 50 CALIFORNIA STREET |
| .9 | SAN FRANCISCO, CA 94111 |
| 20 | ON BEHALF OF TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; |
| 21 | ACTAVIS LLC; ACTAVIS PHARMA, INC.; AND WATSON LABORATORIES, INC.: |
| | |
| 22 | MR. HARVEY BARTLE, IV ATTORNEY AT LAW |
| 23 | 1701 MARKET STREET PHILADELPHIA, PA 19103-2921 |
| 24 | |
| 25 | |

ON BEHALF OF TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC.; AND WATSON LABORATORIES, INC.: MR. JAY P. WALTERS ATTORNEY AT LAW ONE LEADERSHIP SQUARE, 15TH FLOOR 211 NORTH ROBINSON OKLAHOMA CITY, OK 73102

1

2

3 4

5

6

7

8 9

10

11

12

13

14

15

16

17

18 19

20

21

22

23 24

25

PROCEEDINGS

THE COURT: Good morning. I understand we have some that will join us by telephone. We're going to conference in those. I have an e-mail that Kim Jones sent from Odom Sparks. Is everybody that wants to be here that's not here going to connect through this number?

MR. SPARKS: It's my understanding.

THE COURT: Okay. We'll use this phone because I think it'll be easier for Angie to hear.

(Brief pause.)

THE COURT: Good morning. This is Judge Thad Balkman in Cleveland County. Is anybody else on the call?

MR. BRODY: Hi. Good morning, Judge Balkman. This is Steve Brody.

THE COURT: Okay. Good morning, Mr. Brody.

MR. SPARKS: That may be it. I'm not sure.

THE COURT: Okay. If others join the call, I'm sure they can announce themselves.

What I thought I would do, instead of just going around the room like we've done in the past and having people enter appearances, if you have something you would like to say, we'll just ask you at that time to state your name and which party you represent.

I want to welcome everybody here. I know some of you traveled great distances, and I appreciate that. And that's plan it internally.

THE COURT: I hate to say this, but as long as you need.

MR. ODOM: Okay. Thank you, Judge.

THE COURT: You don't have to take me up on it, though.

We're going to take a break, just give you a chance to go to the bathroom, whatever you need to do. Let's be back here at 12:20.

(A recess was taken, after which the following transpired in open court, all parties present:)

THE COURT: All right. Here's what I think we will do. Those depositions that were noticed before the removal that went through the process where you all presented arguments and that Judge Hetherington ruled on, I'm going to decide that those are not void, that they should proceed; that all those before August 30th should go ahead. I'm going to instruct the parties to move forward with those. All others that were pending will be void and will have to be taken up again as if new.

Previously, I had stated that I wanted you to come back here on August 30th, and I think we said at 1:00 -- or maybe 10:00 or 11:00. I'm going to move that to 1:00 p.m. on the 30th, because there's obviously a lot of discovery issues that the parties need to sort through and probably will be

influenced by my decision on the bifurcation motion.

Judge Hetherington will be available Friday, the 31st, in the morning. So I'm trying to make it easy where you're here the afternoon of the 30th and again the morning of the 31st. And so all discovery matters -- well, any pending motions, but particularly the process that was discussed. I think Judge Burrage and the defendants talked about it and Mr. Coats had talked about they had submitted things prior to the removal. You'll have an opportunity to discuss those and argue those with Judge Hetherington at that time.

Just for planning purposes, I want to give you some dates that will be available. Again, you don't have to use them all, but just if you want to have these dates on your calendars in case you need to take up matters related to discovery with Judge Hetherington or with me.

September 20th and October 18th, I think I've previously given you those dates, but if not, I am now.

Also, November 29th, December 20th, January 17th, February 14th. That's Valentine's Day. That's not a good day to be here, but maybe we'll have more love for each other that day. March 14th, April 11th, and I believe there's a status conference May 16th.

MR. COATS: So these are before your Honor?

THE COURT: Yes. These would be before me, or Judge

Hetherington will also be available. But I'm making myself

available those days for this case. If we need more, you can always ask. Hopefully, you don't need more, you need less.

MR. COATS: At 9:00 or 10:00?

THE COURT: Yeah, 9:00. That's fine.

All right. Any other announcements or questions by counsel?

Yes, Mr. Beckworth?

MR. BECKWORTH: Your Honor, just for clarification,
Mr. Duck and I were trying to figure out what you said when you
said void. So for these depositions, do you mean that there'll
be motion practice on them or we need to reissue them or --

THE COURT: I think you'll need to reissue them. You will have to reissue those.

MR. BECKWORTH: And I want to make sure the Court's aware. We reissued those after the remand order.

THE COURT: Okay. So if you've already done that, then I'm not suggesting you have to re -- as long as it was done after the remand.

MR. BECKWORTH: Yes, sir, they were. But we will not be having a hearing on those like we requested or --

THE COURT: Those that were previously noticed and argued and ruled upon by Judge Hetherington and that will take place between now and August 30th, go ahead and do those.

MR. BECKWORTH: And then the ones that we reissued, which were most of the ones on the board, will we be having a

IN THE DISTRICT COURT OF CLEVELAND COUNTY 2 STATE OF OKLAHOMA 3 4 STATE OF OKLAHOMA, ex rel., MIKE HUNTER 5 ATTORNEY GENERAL OF OKLAHOMA, 6 Plaintiff, 7 Case No. CJ-2017-816 vs. 8 (1) PURDUE PHARMA L.P.; (2) PURDUE PHARMA, INC.; 9 (3) THE PURDUE FREDERICK COMPANY; 10 (4) TEVA PHARMACEUTICALS USA, INC; 11 (5) CEPHALON, INC.; (6) JOHNSON & JOHNSON; 12 (7) JANSSEN PHARMACEUTICALS, INC.; 13 (8) ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC., n/k/a JANSSEN PHARMACEUTICALS; (9) JANSSEN PHARMACEUTICA, INC.) 15 n/k/a JANSSEN PHARMACEUTICALS,) INC.; 16 (10) ALLERGAN, PLC, f/k/aACTAVIS PLC, f/k/a ACTAVIS, INC., f/k/a WATSON 17 PHARMACEUTICALS, INC.; 18 (11) WATSON LABORATORIES, INC.;) (12) ACTAVIS LLC; AND 19 (13) ACTAVIS PHARMA, INC., f/k/a WATSON PHARMA, INC., 20 Defendants. 21 22 CERTIFICATE OF THE COURT REPORTER 23 I, Angela Thagard, Certified Shorthand Reporter and 24 Official Court Reporter for Cleveland County, do hereby certify 25 that the foregoing transcript in the above-styled case is a

true, correct, and complete transcript of my shorthand notes of the proceedings in said cause.

I further certify that I am neither related to nor attorney for any interested party nor otherwise interested in the event of said action.

Dated this 11th day of August, 2018.

ANGELA THAGARD, CSR, RPR

EXHIBIT D

IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

| STATE OF OKLAHOMA, ex rel., |) |
|---|------------------------|
| MIKE HUNTER, ATTORNEY GENERAL OF OKLAHOMA, |) |
| ATTORNET GENERAL OF ORLAHOMA, |) |
| Plaintiff, |) |
| , | Case No. CJ-2017-816 |
| vs. |) Judge Thad Balkman |
| |) |
| (1) PURDUE PHARMA L.P.; |) Special Master: |
| (2) PURDUE PHARMA, INC.; |) William Hetherington |
| (3) THE PURDUE FREDERICK COMPANY; |) |
| (4) TEVA PHARMACEUTICALS USA, INC.; |) |
| (5) CEPHALON, INC.; |) |
| (6) JOHNSON & JOHNSON; |) |
| (7) JANSSEN PHARMACEUTICALS, INC; |) |
| (8) ORTHO-MCNEIL-JANSSEN |) |
| PHARMACEUTICALS, INC., n/k/a |) |
| JANSSEN PHARMACEUTICALS; |) |
| (9) JANSSEN PHARMACEUTICA, INC., |) |
| n/k/a JANSSEN PHARMACEUTICALS, INC.; |) |
| (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC, |) |
| f/k/a ACTAVIS, INC., f/k/a WATSON |) |
| PHARMACEUTICALS, INC.; |) |
| (11) WATSON LABORATORIES, INC.; |) |
| (12) ACTAVIS LLC; and |) |
| (13) ACTAVIS PHARMA, INC., |) |
| f/k/a WATSON PHARMA, INC., |) |
| TO 6 1 4 |) |
| Defendants. | |

NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF J&J DEFENDANTS

TO:

VIA email

Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

VIA email

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

COUNSEL FOR THE J&J DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendant, Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica, Inc. (collectively, the "J&J Defendants") in accordance with 12 O.S. §3230(C)(5). The J&J Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the J&J Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

| DATE | TIME | LOCATION |
|-----------------|-----------|-------------------------------|
| August 28, 2018 | 9:00 a.m. | 511 Couch Drive Suite 100 |
| | | Oklahoma City, Oklahoma 73102 |

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the

taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the J&J Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the J&J Defendants, along with all potential witnesses known or reasonable available to the J&J Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 6, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE 512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone: Facsimile:

(405) 516-7800 (405) 516-7859

Emails:

mburrage@whittenburragelaw.com

rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL 313 N.E. 21st Street Oklahoma City, OK 73105

Oklahoma City, OK 73105 Telephone: (405) 521-39

Facsimile:

(405) 521-3921 (405) 521-6246

Emails:

mike.hunter@oag.ok.gov abby.dillsaver@oag.ok.gov

ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave.

Oklahoma City, OK 73102

Telephone:

(405) 601-1616

Email:

gcoffee@glenncoffee.com

ATTORNEYS FOR PLAINTIFF

CERTIFICATE OF SERVICE

I certify that a true and correct copy of the above and foregoing was emailed on August 6, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Paul LaFata Hayden A. Coleman Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

Appendix A

The matters on which examination is requested are itemized below. The J&J Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

1. All actions and efforts previously taken, currently under way, and actions planned and expected to take place in the future which seek to address, fight or abate the opioid crisis.